116 related articles for article (PubMed ID: 10770451)
1. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline.
Morita S; Shimoda K; Someya T; Yoshimura Y; Kamijima K; Kato N
J Clin Psychopharmacol; 2000 Apr; 20(2):141-9. PubMed ID: 10770451
[TBL] [Abstract][Full Text] [Related]
2. The impact of CYP2C19 and CYP2D6 genotypes on metabolism of amitriptyline in Japanese psychiatric patients.
Shimoda K; Someya T; Yokono A; Morita S; Hirokane G; Takahashi S; Okawa M
J Clin Psychopharmacol; 2002 Aug; 22(4):371-8. PubMed ID: 12172336
[TBL] [Abstract][Full Text] [Related]
3. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype.
Dahl ML; Bertilsson L; Nordin C
Psychopharmacology (Berl); 1996 Feb; 123(4):315-9. PubMed ID: 8867869
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.
Yue QY; Zhong ZH; Tybring G; Dalén P; Dahl ML; Bertilsson L; Sjöqvist F
Clin Pharmacol Ther; 1998 Oct; 64(4):384-90. PubMed ID: 9797795
[TBL] [Abstract][Full Text] [Related]
5. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes.
Dalén P; Dahl ML; Bernal Ruiz ML; Nordin J; Bertilsson L
Clin Pharmacol Ther; 1998 Apr; 63(4):444-52. PubMed ID: 9585799
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine.
Shimoda K; Morita S; Hirokane G; Yokono A; Someya T; Takahashi S
Pharmacol Toxicol; 2000 Jun; 86(6):245-9. PubMed ID: 10895986
[TBL] [Abstract][Full Text] [Related]
7. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients.
Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K
J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000
[TBL] [Abstract][Full Text] [Related]
8. Factors Affecting Steady-state Plasma Concentrations of Enantiomeric Mirtazapine and its Desmethylated Metabolites in Japanese Psychiatric Patients.
Hayashi Y; Watanabe T; Aoki A; Ishiguro S; Ueda M; Akiyama K; Kato K; Inoue Y; Tsuchimine S; Yasui-Furukori N; Shimoda K
Pharmacopsychiatry; 2015 Nov; 48(7):279-85. PubMed ID: 26595747
[TBL] [Abstract][Full Text] [Related]
9. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers.
Steimer W; Zöpf K; von Amelunxen S; Pfeiffer H; Bachofer J; Popp J; Messner B; Kissling W; Leucht S
Clin Chem; 2004 Sep; 50(9):1623-33. PubMed ID: 15205367
[TBL] [Abstract][Full Text] [Related]
10. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression.
Murphy GM; Pollock BG; Kirshner MA; Pascoe N; Cheuk W; Mulsant BH; Reynolds CF
Neuropsychopharmacology; 2001 Nov; 25(5):737-43. PubMed ID: 11682257
[TBL] [Abstract][Full Text] [Related]
11. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
Dalén P; Dahl ML; Roh HK; Tybring G; Eichelbaum M; Wilkinson GR; Bertilsson L
Br J Clin Pharmacol; 2003 Jun; 55(6):630-4. PubMed ID: 12814461
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CYP2D6 with low dose (5 mg) paroxetine in patients with high 10-hydroxynortriptyline serum levels-A prospective pharmacokinetic study.
Jessurun NT; Vermeulen Windsant A; Mikes O; van Puijenbroek EP; van Marum RJ; Grootens K; Derijks HJ
Br J Clin Pharmacol; 2021 Mar; 87(3):1529-1532. PubMed ID: 32621544
[TBL] [Abstract][Full Text] [Related]
13. Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry.
Berm E; Kok R; Hak E; Wilffert B
Pharmacopsychiatry; 2016 Sep; 49(5):186-190. PubMed ID: 27101231
[No Abstract] [Full Text] [Related]
14. Quantitative pharmacogenetics of nortriptyline: a novel approach.
Kvist EE; Al-Shurbaji A; Dahl ML; Nordin C; Alván G; Ståhle L
Clin Pharmacokinet; 2001; 40(11):869-77. PubMed ID: 11735606
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
16. Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia.
Yasui-Furukori N; Mihara K; Kondo T; Kubota T; Iga T; Takarada Y; De Vries R; Kaneko S; Tateishi T
J Clin Pharmacol; 2003 Feb; 43(2):122-7. PubMed ID: 12616663
[TBL] [Abstract][Full Text] [Related]
17. Effects of Pharmacogenetic Screening for CYP2D6 Among Elderly Starting Therapy With Nortriptyline or Venlafaxine: A Pragmatic Randomized Controlled Trial (CYSCE Trial).
van der Schans J; Hak E; Postma M; Breuning L; Brouwers JRBJ; Ditters K; Jansen PAF; Kok RM; Maring JG; van Marum R; Mulder H; Nanninga J; Oude Voshaar RC; Risselada AJ; Vleugel L; Stek M; van Schaik RHN; Berm EJJ; Wilffert B
J Clin Psychopharmacol; 2019; 39(6):583-590. PubMed ID: 31688392
[TBL] [Abstract][Full Text] [Related]
18. Effect of CYP2D6 genotypes on the metabolism of haloperidol in a Japanese psychiatric population.
Someya T; Shimoda K; Suzuki Y; Sato S; Kawashima Y; Hirokane G; Morita S; Yokono A; Takahashi S
Neuropsychopharmacology; 2003 Aug; 28(8):1501-5. PubMed ID: 12784098
[TBL] [Abstract][Full Text] [Related]
19. Sequence-based CYP2D6 genotyping in the Korean population.
Lee SY; Sohn KM; Ryu JY; Yoon YR; Shin JG; Kim JW
Ther Drug Monit; 2006 Jun; 28(3):382-7. PubMed ID: 16778723
[TBL] [Abstract][Full Text] [Related]
20. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
